Quick Answer: Medicare Part D and Medicare Advantage Prescription Drug plans (MA-PD) both cover prescription drugs in 2026, but they route through different structures with very different premiums. Standalone Part D Prescription Drug Plans (PDPs), paired with Original Medicare, average $36 per month in 2026, while Medicare Advantage plans that bundle drug coverage (MA-PD) average just $8 per month for the drug portion, and roughly 75 percent of MA-PD enrollees pay no supplemental premium at all beyond the standard $202.90 Part B premium. Both pathways must follow the same federally defined 2026 Part D benefit design set by the Inflation Reduction Act of 2022: a $615 maximum standard deductible, 25 percent coinsurance in the initial coverage phase, and a $2,100 annual out-of-pocket cap after which the plan pays 100 percent for the rest of the year. Medicare Advantage plans typically cost less on premium because CMS pays MA insurers rebate dollars that plans can apply toward Part D premium reductions, but MA-PD plans also use more prior authorization and narrower pharmacy and provider networks than a standalone PDP. In 2026, 56 percent of the 56.3 million total Part D enrollees, or about 31.4 million people, are in MA-PD plans, versus 24.9 million in standalone PDPs. Extra Help (the Low-Income Subsidy) covers premiums, deductibles, and most cost-sharing for eligible low-income beneficiaries under either pathway.
Medicare Part D is the federal prescription drug benefit that beneficiaries can access two ways in 2026: through a standalone Part D Prescription Drug Plan (PDP) purchased alongside Original Medicare, or through a Medicare Advantage plan that bundles drug coverage into the same policy as hospital and medical benefits, called an MA-PD. Both delivery methods must offer the same federally standardized Part D benefit design for 2026, including the $615 maximum deductible and the $2,100 annual out-of-pocket cap created by the Inflation Reduction Act of 2022. The Centers for Medicare & Medicaid Services (CMS) reports that 56.3 million people are enrolled in Part D coverage for 2026, split between 24.9 million standalone PDP enrollees and 31.4 million MA-PD enrollees, meaning 56 percent of all Part D beneficiaries now get their drug coverage bundled inside a Medicare Advantage plan rather than through a separate PDP.
Medicare Advantage insurers received an average of $2,664 per enrollee in 2026 above their estimated costs, largely from CMS quality bonus payments and risk-adjustment rebates, and roughly 26 percent of that rebate money goes toward reducing the plan's Part D premium. That rebate subsidy is the main reason the average MA-PD drug premium fell to just $8 per month in 2026 compared with $36 per month for a standalone PDP, a gap KFF describes as the MA-PD premium running more than four times lower than the standalone PDP average. Standalone PDPs cannot draw on the same medical-benefit rebate pool because they only sell drug coverage, so their premium reflects drug costs alone. Beneficiaries should not assume the lower MA-PD premium is free money, however, because Medicare Advantage plans typically apply more prior authorization, narrower formulary tiers, and preferred-pharmacy network restrictions that a standalone PDP paired with Original Medicare may not.
The Inflation Reduction Act of 2022 built several cost protections that apply identically whether a beneficiary chooses a standalone PDP or an MA-PD in 2026. The $35 monthly insulin cap, the $2,100 annual Part D out-of-pocket cap, the requirement that every Part D sponsor offer the Medicare Prescription Payment Plan (a $0-interest option to spread out-of-pocket drug costs into monthly installments across the calendar year instead of paying it all at the pharmacy counter), and the Medicare Drug Price Negotiation Program's Maximum Fair Price for negotiated drugs all apply the same way under either pathway. Extra Help, the Low-Income Subsidy program for beneficiaries near 150 percent of the federal poverty level in 2026, similarly reduces premiums, deductibles, and copays no matter which type of plan a beneficiary selects, and CMS reports 13.6 million people receive Extra Help in 2026, with 68 percent of them enrolled in MA-PD plans and 32 percent in standalone PDPs.
What Part D vs. Medicare Advantage Rx Costs by Point of Pay (2026)
The price you pay depends almost entirely on WHERE you pay. The same part d vs. medicare advantage rx can cost many times more at a hospital than at your local pharmacy:
2026 Part D vs. Medicare Advantage Rx Price by Point of Pay| Where you pay | Typical cost | Notes |
|---|
| Standalone Part D Prescription Drug Plan (PDP) average premium | $36/month (2026) | Paired with Original Medicare. Down from $39/month in 2025 after CMS negotiated bid terms with PDP sponsors. |
| Medicare Advantage Prescription Drug plan (MA-PD) average drug premium | $8/month (2026) | About 75% of MA-PD enrollees pay $0 in supplemental premium beyond the standard $202.90 Part B premium in 2026. |
| Annual Part D deductible (2026 standard maximum) | Up to $615/year | Identical for PDP and MA-PD; some plans offer a lower or $0 deductible on select formulary tiers. |
| Annual Part D out-of-pocket cap (catastrophic coverage) | $2,100/year then $0 (2026) | Set by the Inflation Reduction Act of 2022; applies identically to PDP and MA-PD enrollees for the rest of the calendar year. |
| Extra Help (Low-Income Subsidy) enrollee cost-share | $0 premium/deductible; $5.10 generic / $12.65 brand copay (2026) | Available to enrollees at or below 150% of the federal poverty level in 2026, regardless of PDP or MA-PD enrollment. |
Premium figures reflect CMS and KFF 2026 realized averages, not the CMS advance-notice estimate. Actual premiums, deductibles, and copays vary by the specific plan a beneficiary selects.
Source: CMS 2026 Medicare Advantage and Part D Rate Announcement, KFF Medicare Part D Enrollment Premiums and Cost Sharing in 2026, Social Security Administration Extra Help program
Why Hospitals Charge So Much
Prior authorization explains much of the day-to-day cost and hassle difference between the two pathways in 2026. CMS data shows 99 percent of Medicare Advantage enrollees are in plans that require prior authorization for at least some services, including 94 percent of plans requiring it for certain Part B-administered drugs, compared with lighter utilization management on many standalone Part D plans paired with Original Medicare. A beneficiary whose cardiologist prescribes a specialty formulary-tier drug may need a prior authorization approval from the MA-PD plan before the pharmacy can fill it, adding days or weeks of delay that a standalone PDP enrollee might not face for the same drug.
Pharmacy network structure is the second major driver of cost differences. Both PDP and MA-PD plans designate certain pharmacies as preferred, meaning the plan negotiated a lower cost-sharing tier at that pharmacy chain, and other pharmacies as standard network, where the same drug can cost two to four times more in copay for an identical prescription. Walmart and Costco frequently sit in the preferred tier for many 2026 Part D formularies because of negotiated generic dispensing fees, while CVS and Walgreens are sometimes priced as standard network on lower-premium plans, so the pharmacy a beneficiary chooses can matter as much as which plan type they pick.
Medicare Advantage's narrower provider network compounds these formulary differences for beneficiaries managing chronic conditions. KFF reports Medicare Advantage enrollees have access to roughly half the physicians available to Original Medicare beneficiaries, and more than 61 percent of MA enrollees are in HMO plans that generally do not cover out-of-network care at all. A beneficiary who needs a specialist to prescribe or manage a high-cost specialty drug should confirm that specialist is in-network before assuming the MA-PD's lower drug premium translates into lower total cost of care.
Patient Assistance Programs
Extra Help (the Low-Income Subsidy) is the primary government cost-reduction program available under both standalone Part D and Medicare Advantage drug coverage in 2026, and it works identically no matter which pathway a beneficiary chooses:
Patient assistance programs for Part D vs. Medicare Advantage Rx| Manufacturer program | Cost / Benefit | How to apply |
|---|
| Extra Help (Low-Income Subsidy, LIS) | $0 premium, $0 deductible, and copays capped at $5.10 for generics and $12.65 for brand-name drugs in 2026, applied automatically to either a standalone PDP or an MA-PD plan | ssa.gov/medicare/part-d-extra-help |
| Medicare Savings Programs (state Medicaid agency) | Automatic full Extra Help enrollment for dual-eligible beneficiaries who qualify for a state Medicare Savings Program in 2026, regardless of PDP or MA-PD enrollment | medicaid.gov/medicare-savings-programs |
| State Pharmaceutical Assistance Programs (SPAPs) | Additional state-funded premium and copay help in states that operate a SPAP, layered on top of Extra Help or standalone from it, available to enrollees in either plan type | medicare.gov/pharmaceutical-assistance-program |
| Medicare Prescription Payment Plan (M3P) | $0-interest monthly installment option that spreads out-of-pocket drug costs across the rest of the calendar year instead of paying the full amount at the pharmacy, available under every 2026 PDP and MA-PD plan | medicare.gov/prescription-payment-plan |
Federal anti-kickback law (42 U.S.C. section 1320a-7b) bars drug manufacturers from offering a copay card or manufacturer coupon to anyone enrolled in Medicare, Medicaid, TRICARE, or VA coverage, whether that Medicare coverage is a standalone Part D plan or a Medicare Advantage Prescription Drug plan. Beneficiaries who need help affording a specific brand-name drug should apply for Extra Help first, then check that manufacturer's income-based patient assistance program, which operates outside the anti-kickback restriction because it does not depend on insurance status.
Source: Social Security Administration Extra Help program, Medicare.gov Prescription Payment Plan, Medicaid.gov Medicare Savings Programs, CMS State Pharmaceutical Assistance Program directory
Medicare Part D
Medicare Part D's 2026 benefit design applies identically to standalone PDPs and MA-PD plans: enrollees pay up to a $615 deductible, then 25 percent coinsurance during the initial coverage phase, until total out-of-pocket spending on covered drugs reaches $2,100 for the year, after which the plan pays 100 percent of covered drug costs for the remainder of the calendar year. The Inflation Reduction Act of 2022 eliminated the old coverage gap phase entirely starting in 2025, so the deductible-to-catastrophic structure described here is now the complete Part D benefit curve for 2026, whether a beneficiary is enrolled in a PDP or an MA-PD.
The Medicare Prescription Payment Plan, sometimes called M3P or the smoothing program, lets any Part D enrollee, in a PDP or MA-PD, opt to pay their out-of-pocket drug costs in monthly installments spread across the rest of the calendar year instead of the full amount at the pharmacy counter, at $0 interest. Enrollees who expect high drug costs early in the year, such as someone starting a new specialty medication in January, are the most common users of the Payment Plan, since it converts a large upfront pharmacy bill into a predictable monthly charge through December.
Common Part D vs. Medicare Advantage Rx Billing Errors
Choosing between a PDP and an MA-PD, and switching between them, carries its own set of common mistakes in 2026. Watch for these before you enroll or file a claim:
- Enrolling in a standalone Part D PDP while already enrolled in a Medicare Advantage plan without drug coverage restrictions, which can trigger automatic disenrollment from the MA plan back to Original Medicare.
- Assuming a $0 premium MA-PD plan means $0 drug cost. The premium covers plan access only; deductible, coinsurance, and copay still apply up to the $2,100 out-of-pocket cap in 2026.
- Filling a prescription at a standard-network pharmacy without checking whether a preferred-network pharmacy like Walmart or Costco charges a lower 2026 copay for the identical drug.
- Missing the Medicare Advantage Open Enrollment Period (January 1 to March 31) window to switch from an MA-PD plan back to Original Medicare plus a standalone PDP after realizing the network or formulary does not fit.
- Applying a manufacturer copay card or manufacturer coupon to a Part D or MA-PD claim, which federal anti-kickback law prohibits and can trigger a clawback from the pharmacy.
- Comparing only the monthly premium between a PDP and an MA-PD without also comparing the plan's formulary tier placement and prior authorization rules for the specific drugs a beneficiary takes, which often matters more than the premium difference.
Frequently Asked Questions
Does my drug's generic or biosimilar status change if I switch from a standalone Part D plan to Medicare Advantage?
No. Generic and biosimilar availability is determined by FDA approval and each plan's formulary, not by whether you are enrolled in a standalone Part D Prescription Drug Plan (PDP) or a Medicare Advantage Prescription Drug plan (MA-PD). CMS requires every 2026 Part D formulary, PDP or MA-PD, to cover at least two drugs in each therapeutic category and to include generics and FDA-approved biosimilars where the FDA has approved one. What can change between plans is the formulary tier a generic or biosimilar sits on, which affects your copay even when the drug itself is identical.
How do I apply for Extra Help, the Medicare Part D patient assistance program?
Apply online at ssa.gov/medicare/part-d-extra-help, by phone at 1-800-772-1213, or at a local Social Security office. You will need proof of income and resources, since 2026 eligibility requires income near 150 percent of the federal poverty level and resources under $16,590 for an individual or $33,100 for a couple. If approved, Social Security automatically notifies your current Part D plan, whether it is a standalone PDP or an MA-PD, and your premium, deductible, and copays drop immediately. Reapplication happens automatically each year based on updated income data.
Can I use a manufacturer copay card with Medicare Part D or Medicare Advantage?
No. Federal anti-kickback law prohibits drug manufacturers from offering a copay card or manufacturer coupon to anyone with Medicare coverage, including both standalone Part D plans and Medicare Advantage Prescription Drug plans. This restriction applies the same way regardless of which pathway covers your prescription. Instead, apply for Extra Help if your income qualifies, or contact the manufacturer's separate income-based patient assistance program, which most manufacturers operate independently from their commercial copay card.
What if my Part D or Medicare Advantage plan denies coverage for a drug?
Request the plan's written coverage determination, then file a formal redetermination appeal within 60 days, including your prescriber's statement of medical necessity. This process is identical whether you are enrolled in a standalone PDP or an MA-PD plan, because CMS regulates both under the same Part D appeals rules. If the plan upholds the denial, an independent CMS contractor called the Independent Review Entity conducts a second-level review, followed by an Administrative Law Judge hearing if the dollar amount qualifies.
Does the IRA's Maximum Fair Price apply differently under Part D versus Medicare Advantage?
No. The Inflation Reduction Act's Medicare Drug Price Negotiation Program sets one Maximum Fair Price per negotiated drug that applies uniformly whether a beneficiary is enrolled in a standalone Part D Prescription Drug Plan or a Medicare Advantage Prescription Drug plan in 2026. Both plan types must pass the negotiated savings through to enrollees in the same way, so your out-of-pocket cost for a negotiated drug like Eliquis or Jardiance does not change based on which pathway covers your Part D benefit.
What does prescription drug coverage cost without insurance compared to Part D or Medicare Advantage in 2026?
Paying cash without any Part D coverage means paying the pharmacy's full retail price with no deductible-to-cap structure protecting you, which can run hundreds of dollars a month for a single brand-name drug. Enrolling in either a standalone Part D plan, averaging $36 per month in 2026, or an MA-PD plan, averaging $8 per month for the drug portion, caps your annual out-of-pocket drug spending at $2,100 in 2026 once you hit the deductible and initial coverage phase. For most beneficiaries taking regular prescriptions, either Part D pathway costs far less over a full year than paying cash.
Do I qualify for Extra Help under a Part D or Medicare Advantage plan in 2026?
You may qualify for Extra Help in 2026 if your income is at or below 150 percent of the federal poverty level, which is $23,940 for an individual or $32,460 for a married couple, and your resources are under $16,590 for an individual or $33,100 for a couple. Eligibility works identically whether you are enrolled in a standalone Part D plan or a Medicare Advantage plan with drug coverage. Beneficiaries who already qualify for full Medicaid, a Medicare Savings Program, or Supplemental Security Income are automatically enrolled in full Extra Help without a separate application.
What is the difference between a standalone Part D plan (PDP) and a Medicare Advantage Prescription Drug plan (MA-PD)?
A standalone Part D Prescription Drug Plan (PDP) is a separate drug-only policy you buy alongside Original Medicare, averaging $36 per month in 2026. A Medicare Advantage Prescription Drug plan (MA-PD) bundles drug coverage into the same policy as your hospital and medical benefits, averaging just $8 per month for the drug portion in 2026 because Medicare Advantage insurers apply CMS rebate payments toward lowering the premium. Both must follow the same 2026 Part D benefit design, but MA-PD plans generally require more prior authorization and offer narrower pharmacy and physician networks than a standalone PDP paired with Original Medicare.
